(Reuters) - Drugmakers are looking for some kind of indemnity from governments or multilateral agencies against possible losses or claims arising from the widespread emergency use of new Ebola vaccines in Africa.
While the issue will not delay the industry’s work to accelerate production and clinical testing of three experimental vaccines, it is likely to be discussed at a high-level meeting in Geneva on Thursday.
World Health Organization (WHO) Director-General Margaret Chan will chair the meeting, which includes industry executives, representatives from countries including those affected by Ebola, drug regulators and funders.
Help employers find you! Check out all the jobs and post your resume.
